Influence of BGP-15, a nicotinic amidoxime derivative, on the vascularization and growth of murine hepatoma xenografts

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1023-1028

  Kardon, Tamás ^a   Nagy, Gábor ^a   Csala, Miklós ^a   Kiss, András ^a   Schaff, Zsuzsa ^a   Nagy, Péter Literáti ^b   Wunderlich, Livius ^a   Bánhegyi, Gábor ^a   Mandl, József ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b N Gene Research Laboratories   (Hungary)

Author keywords

Angiogenesis suppression; BGP 15; Hepatoma xenografts; Nicotinic amidoxime derivative; VEGF

Indexed keywords

GLUCOSE TRANSPORTER 1; MESSENGER RNA; O (2 HYDROXY 3 PIPERIDINOPROPYL)NICOTINIC AMIDOXIME; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATOMA CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; FEMALE; GLUCOSE TRANSPORTER TYPE 1; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MITOSIS; NEOVASCULARIZATION, PATHOLOGIC; OXIMES; PIPERIDINES; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645802632     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
2. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
3. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
4. Madhusudan S and Harris AL: Drug inhibition of angiogenesis. Curr Opin Pharmacol 2: 403-414, 2002.
5. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395, 2000.
6. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD and McDonald DM: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165: 35-52, 2004.
7. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T and Fukui H: Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 39: 1517-1524, 2004.
8. Maulik N and Das DK: Redox signaling in vascular angiogenesis. Free Rad Biol Med 33: 1047-1060, 2002.
9. Vigh L, Literati PN, Horvath I, Torok Z, Balogh G, Glatz A, Kovacs E, Boros I, Ferdinandy P, Farkas B, Jaszlits L, Jednakovits A, Koranyi L and Maresca B: Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nature Med 3: 1150-1154, 1997.
10. Szabados E, Literati-Nagy P, Farkas B and Sumegi B: BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem Pharmacol 59: 937-945, 2000.
11. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G and Greensmith L: Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10: 402-405, 2004.
12. Nanasi PP and Jednakovits A: Multilateral in vivo and in vitro protective effect of the novel heat shock protein coinducer, Bimoclomol: results of preclinical studies. Cardiovasc Drug Rev 19: 133-151, 2001.
13. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW and Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth. Proc Natl Acad Sci 94: 8104-8109, 1997.
14. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
15. Sambrook J and Russell DW: Protocols 6-8. In: Molecular Cloning: A Laboratory Manual. Sambrook J and Russell DW (eds.), 3rd edn., New York, Cold Spring Harbour Laboratory Press, pp. 7.31-7.45, 2001.
16. Hagedorn M and Bikfalvi A: Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol 34: 89-110, 2000.
17. Cao Z, Fang J, Xia C, Shi X and Jiang BH: trans-3,4,5′- Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 10: 5253-5263, 2004.
18. Arsham AM, Plas DR, Thompson CB and Simon MC: Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res 64: 3500-3507, 2004.